Progression-free survival for patients with CLL progressing after idelalisib who are treated with venetoclax. Shown is the Kaplan-Meier curve for investigator-assessed progression-free survival for all 36 patients from the main and expansion cohorts. Below the curve is the number of patients at risk for the event at each time. Tick marks represent patients censored for each outcome measure.